英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

damnification    
n. 损伤,损害

损伤,损害

Damnification \Dam`ni*fi*ca"tion\, n. [LL. damnificatio.]
That which causes damage or loss.
[1913 Webster]

DAMNIFICATION. That which causes a loss or damage to a society, or to one
who has indemnified another. For example, when a society has entered into an
obligation to pay the debt of the principal, and the principal has become
bound in a bond to indemnify the surety, the latter has suffered a
damnification the moment he becomes liable to be sued for the debt of the
principal - and it has been held in an action brought by the surety, upon a
bond of indemnity, that the terror of suit, so that the surety dare not go
about his business, is a damnification. Ow. 19; 2 Chit. R. 487; 1 Saund.
116; 8 East, 593; Cary, 26.
2. A judgment fairly obtained against a party for a cause against which
another person is bound to indemnify him, with timely notice to that person
of the bringing of the action, is admissible as evidence in an action
brought against the guarantor on the indemnity. 7 Cranch, 300, 322. See F.
N. B. Warrantia Chartae; Lib. Int. Index, Warrantia Chartae; 2 S. & R. 12,
13.


请选择你想看的字典辞典:
单词字典翻译
DAMNIFICATION查看 DAMNIFICATION 在百度字典中的解释百度英翻中〔查看〕
DAMNIFICATION查看 DAMNIFICATION 在Google字典中的解释Google英翻中〔查看〕
DAMNIFICATION查看 DAMNIFICATION 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced NSCLC, BCC, CSCC, as an adjuvant treatment for high-risk CSCC Review Important Safety Info Full Prescribing Information including Med Guide
  • Libtayo: Uses, Side Effects, Warnings - Drugs. com
    Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer Includes Libtayo side effects, interactions and indications
  • LIBTAYO® (cemiplimab-rwlc) for Treatment in Advanced CSCC
    LIBTAYO® (cemiplimab-rwlc) is indicated for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (laCSCC or mCSCC) who are not candidates for curative surgery or curative radiation Review Important Safety Information and full Prescribing Information
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • Cemiplimab-rwlc (Libtayo®) - OncoLink
    Cemiplimab-rwlc is a type of monoclonal antibody therapy used in the treatment of some cases of cutaneous squamous cell carcinoma
  • Cemiplimab (Libtayo®) - ChemoExperts
    Treatment Name: Cemiplimab (Libtayo®) Cemiplimab (Libtayo®) is an Immunotherapy Regimen for Lung Cancer, Non-Small Cell Lung Cancer (NSCLC) How does cemiplimab work? Cemiplimab is designed to block the signals that tumor cells use to suppress the immune system allowing the immune system to attack the lung cancer cells Goals of therapy:
  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • LIBTAYO (cemiplimab-rwlc) Label - Food and Drug Administration
    LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation (1)
  • LIBTAYO® Full Prescribing Information | Regeneron
    LIBTAYO (cemiplimab-rwlc) injection for intravenous use is a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution with a pH of 6
  • Taking LIBTAYO® (cemiplimab-rwlc) | Advanced CSCC
    LIBTAYO® (cemiplimab-rwlc) is a prescription IV infusion given for 30 minutes every 3 weeks Review Important Safety Info Full Prescribing Information including Med Guide





中文字典-英文字典  2005-2009